Artikel: Hypophosphorémie après traitement par fer injectable chez l’adulte : comparaison entre le carboxymaltose ferrique et l’hydroxyde ferrique-saccharose.
Annales pharmaceutiques francaises
2023 Band 81, Heft 5, Seite(n) 790–800
Abstract: Hypophosphatemia is a recognized side effect of treatment of iron deficiency anemias with injectable iron. We analyzed 35 clinical trials that used ferric carboxymaltose (FCM) or iron sucrose (IS). Hypophosphatemia prevalence ranged from 0 to 91.7%. FCM- ... ...
| Titelübersetzung | Hypophosphatemia after injectable iron treatments in adults: Comparison between ferric carboxymaltose and iron sucrose. |
|---|---|
| Abstract | Hypophosphatemia is a recognized side effect of treatment of iron deficiency anemias with injectable iron. We analyzed 35 clinical trials that used ferric carboxymaltose (FCM) or iron sucrose (IS). Hypophosphatemia prevalence ranged from 0 to 91.7%. FCM-induced a significant (P<0.001) greater hypophosphatemia prevalence and phosphatemia decrease than IS (52.0% [95% CI: 42.2-61.8%] vs. 7.7% [95% CI: -2.8 to 18.2%] and -1.12mmol/L [95% CI: -1.36 to -0.89mmol/L] vs. -0.13mmol/L [95% CI: -0.59 to 0.32mmol/L]). FCM-induced hypophosphatemia was dose-dependent. The nadir of hypophosphatemia was reached in almost all studies after 7 and 14days. Hypophosphatemia persisted at the end of the study in 53.8% of the reported studies that used FCM and lasted up to 6months. FCM-induced an increase in intact circulating fibroblast growth factor 23 and in renal phosphorus excretion while serum 1-25 dihydroxyvitamin D was decreased. Risk factors for hypophosphatemia after FCM therapy were low basal circulating phosphate or ferritin, low body weight, high glomerular filtration rate, serum parathyroid hormone or hemoglobin and age, whereas renal insufficiency was associated with a lower risk. In conclusion, hypophosphatemia is common after treatment with injectable iron, FCM being associated with a higher risk than IS and with disorders of phosphocalcium metabolism. Monitoring of blood phosphate and 1-25 dihydroxyvitamin D could be considered during FCM therapy. |
| Mesh-Begriff(e) | Adult ; Humans ; Iron/adverse effects ; Ferric Oxide, Saccharated/adverse effects ; Hypophosphatemia/chemically induced ; Hypophosphatemia/epidemiology ; Phosphates/adverse effects |
| Chemische Substanzen | Iron (E1UOL152H7) ; ferric carboxymaltose (6897GXD6OE) ; Ferric Oxide, Saccharated (FZ7NYF5N8L) ; Phosphates |
| Sprache | Französisch |
| Erscheinungsdatum | 2023-03-22 |
| Erscheinungsland | France |
| Dokumenttyp | English Abstract ; Journal Article ; Review |
| ZDB-ID | 307-4 |
| ISSN | 0003-4509 |
| ISSN | 0003-4509 |
| DOI | 10.1016/j.pharma.2023.03.003 |
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Zs.A 223: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.